Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 20/20 | 0.87 |
| ▸ | CNR2 | P34972 | 7/20 | 0.87 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.87 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3475455 | 1.00 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL16357820 | 0.94 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL16359327 | 0.94 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL1896441 | 0.94 | CNR1 (0.87) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL13253294 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL304925 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL4024243 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL17565778 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| Taranabant SCHEMBL501972 | 0.93 | CNR1 (1.00) | CNR1CNR2CYP2D6CYP2C9KCNH2 | |
| SCHEMBL13237168 | 0.93 | CNR1 (0.86) | CNR1CNR2CYP2D6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7754188-B2 | Radiolabeled cannabinoid-1 receptor modulators | MERCK SHARP & DOHME CORP. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20060115425-A1 | Substituted amides | MERCK SHARP & DOHME CORP. | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060115425-A1 | Substituted amides | CNR1, CNR2, FAAH | CNR1 1/4885CNR2 2/4885CYP2D6 1549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.